



## **Evoke Pharma's Abstract Entitled "Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients" to Be Presented at The American College of Gastroenterology (ACG) 2023 An**

October 18, 2023

### **Selected for a Distinguished Oral Plenary Presentation**

SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- [Evoke Pharma, Inc. \(NASDAQ: EVOK\)](#), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI<sup>®</sup> (metoclopramide) nasal spray, announced that its real-world healthcare utilization data suggesting reduced healthcare costs for patients on GIMOTI versus patients on oral metoclopramide will be presented, as an oral plenary presentation, at the American College of Gastroenterology annual meeting taking place in Vancouver, BC, Canada from October 20-25, 2023.

The authors of the abstract include Richard McCallum, MD (Texas Tech University-EI Paso), Michael Cline, DO (Cleveland Clinic) and David Kunkel, MD (University of California, San Diego), which will be presented orally in a distinguished plenary session at the meeting. These new data build upon the findings presented in plenary session at Digestive Disease Week (DDW) earlier this year which demonstrated significant reductions in healthcare resource utilization (e.g., office, emergency department (ER) and hospital visits, etc.).

During the ACG plenary session next week, the authors will examine additional quantifiable insights related to impact on total healthcare costs that illustrate the potential broad benefits of GIMOTI, the only outpatient non-oral product in the U.S. labelled for the treatment of acute and recurrent diabetic gastroparesis (DGP).

"This is the first study to show nasal treatment of diabetic gastroparesis patients not only significantly reduces the number of ER visits and hospitalizations, but also the costs of treatment, even when compared to a generic," said Michael Cline, DO, Head of the Gastroparesis Clinic, Cleveland Clinic, Ohio.

Upon identifying a major gap in gastroparesis treatment, Evoke developed GIMOTI as a nasal spray to specifically by-pass erratic absorption issues that DGP patients often suffer with medications that are in tablet or pill form. Patients with long-standing diabetes can develop gastroparesis (a delay in stomach emptying). In fact, many commonly used agents to treat symptoms associated with gastroparesis (opioids- abdominal pain, ondansetron and promethazine- nausea) or co-morbid conditions (proton pump inhibitors- GERD) as well as medications used to treat diabetes (GLP-1 receptor agonists) may exacerbate delayed gastric emptying.

"With the lack of effective oral treatments, and the promising findings for GIMOTI, Evoke is dedicated to make GIMOTI the standard of care for patients with diabetic gastroparesis," said Dave Gonyer, R.Ph., Evoke Pharma CEO.

Details of the abstract as follows:

**Title:** Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients

**Presentation Number:** 67

**Presentation Date/Time:** Wednesday, October 25 8:50 A.M. PDT

**Location:** Vancouver Convention Centre (West Building)

#### **About Evoke Pharma, Inc.**

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.

Visit [www.EvokePharma.com](http://www.EvokePharma.com) for more information.

Follow GIMOTI on [Facebook](#)

Follow Evoke Pharma on [Facebook](#)

Follow Evoke Pharma on [LinkedIn](#)

Follow Evoke Pharma on [Twitter](#)

## **About EVERSANA**

EVERSANA® is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit [eversana.com](http://eversana.com) or connect through [LinkedIn](#) and [Twitter](#).

## **Safe Harbor Statement**

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding: GIMOTI's potential to reduce healthcare resource utilization by diabetic gastroparesis patents; and Evoke's belief that GIMOTI can improve treatment of diabetic gastroparesis. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke's business, including, without limitation: Evoke's and EVERSANA's ability to successfully drive market demand for GIMOTI; Evoke's ability to obtain, maintain and successfully enforce intellectual property protection for GIMOTI; the results of market research studies may not predict acceptance by patients, healthcare providers or payors; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke's ability to obtain additional financing as needed to support its operations; Evoke is entirely dependent on the success of GIMOTI; Evoke's dependence on third parties for the manufacture of GIMOTI; and other risks and uncertainties detailed in Evoke's prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

## **Investor Contact:**

Daniel Kontoh-Boateng

DKB Partners

Tel: 862-213-1398

[dboateng@dkbpartners.net](mailto:dboateng@dkbpartners.net)



Source: Evoke Pharma, Inc.